Cypherpunk Technologies Inc., formerly Leap Therapeutics, reports developments tied to its transition from an oncology biotechnology company into an issuer with a digital asset treasury strategy focused on Zcash and its native coin, ZEC. The company changed its name in 2025, while continuing cancer research and development through a wholly owned subsidiary using the Leap Therapeutics name.
Recurring updates include ZEC treasury acquisitions, financing and capital-structure actions, board and leadership changes, quarterly financial results, and oncology program disclosures. The therapeutic pipeline referenced in company updates includes sirexatamab (DKN-01), a monoclonal antibody targeting DKK1, and FL-501, a monoclonal antibody targeting GDF-15.
Leap Therapeutics (Nasdaq:LPTX) announced a corporate overview presentation at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. Douglas E. Onsi, the company’s President and CEO, will present on January 11 at 6:00 a.m. Eastern Time. The presentation can be accessed on the company’s Investors page, with a replay available for a limited time. Leap is known for its immuno-oncology therapeutics, including the clinical candidate DKN-01, targeting various cancers.
Leap Therapeutics (Nasdaq:LPTX) announced that President and CEO Douglas E. Onsi will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 3:40 p.m. ET. The presentation will be available via webcast on the company's Investors page. Leap focuses on developing targeted and immuno-oncology therapeutics, with its lead candidate, DKN-01, currently in clinical trials for various cancers. The company has a strategic partnership with BeiGene for DKN-01's development in Asia, excluding Japan.
Leap Therapeutics (Nasdaq:LPTX) announced the publication of preclinical results regarding DKN-01 in Molecular Cancer Research. DKN-01, a monoclonal antibody blocking the DKK1 protein, showed positive effects in mouse cancer models including tumor growth inhibition. The studies indicated that DKN-01 can activate NK cells and reduce metastases, suggesting its potential effectiveness in combination with PD-1 inhibitors. Leap has also initiated trials combining DKN-01 with BeiGene's tislelizumab for patients with high DKK1 levels in gastroesophageal cancers.
Leap Therapeutics, Inc. (Nasdaq:LPTX) announced that CEO Douglas E. Onsi will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. A pre-recording of the chat is accessible on the company’s investors page, with a replay available for 90 days. Leap focuses on developing targeted and immuno-oncology therapeutics, with DKN-01 as their lead candidate, currently in clinical trials for various cancers. The company collaborates with BeiGene for DKN-01's development in Asia, Australia, and New Zealand.
Leap Therapeutics, Inc. (Nasdaq:LPTX) reported its Q3 2020 financial results, showing a net loss of $7.1 million, down from $7.9 million in Q3 2019. Key highlights include the first patient dosed in a Phase 2a study of DKN-01 in combination with BeiGene's tislelizumab for metastatic gastric cancer. The FDA granted Fast Track designation to DKN-01 for high DKK1 expression G/GEJ cancer. The company ended the quarter with $58 million in cash and marketable securities, highlighting effective cost management with R&D expenses at $5.4 million, down from $5.8 million year-over-year.
Leap Therapeutics (Nasdaq:LPTX) announced that its President and CEO, Douglas E. Onsi, will present a corporate overview at the Stifel 2020 Virtual Healthcare Conference from November 16-18, 2020. The presentation is scheduled for November 16 at 9:20 a.m. ET and will be available via live webcast on the company's Investors page. Leap is focused on developing targeted and immuno-oncology therapeutics, with its lead candidate, DKN-01, currently in clinical trials for various cancers. Further details on Leap can be found on their official website.
Leap Therapeutics (Nasdaq:LPTX) presented clinical data from its Phase 2 trial of DKN-01 for recurrent epithelial endometrial cancers at the AACR Virtual Conference on November 9-10, 2020. DKN-01, a monoclonal antibody targeting Dickkopf-1 (DKK1), showed efficacy in biomarker-selected patients, particularly those with Wnt signaling alterations. Key findings included a 10% overall response rate and improved outcomes in patients with Wnt activating mutations and high DKK1 expression. The study suggests DKN-01 offers a promising treatment option with a favorable safety profile.
Leap Therapeutics (Nasdaq: LPTX) announced promising results from a Phase 1b/2a clinical trial of DKN-01 for advanced esophagogastric cancer presented at the SITC 2020 Annual Meeting. The study revealed that patients with high tumoral DKK1 expression had superior clinical outcomes, including doubled median progression-free survival (PFS) and better overall survival (OS) rates, as compared to those with low DKK1 levels. These findings suggest that DKK1 expression could serve as a predictive biomarker, supporting further studies combining DKN-01 with anti-PD-1 therapies.
Leap Therapeutics, a biotechnology company, will present crucial data on its DKN-01 monoclonal antibody for esophagogastric cancer at the Society of Immunotherapy of Cancer's (SITC) 35th Annual Meeting, from November 9-14, 2020. Dr. Samuel J. Klempner will present findings that show DKK1 expression correlates with improved clinical outcomes in patients. DKN-01, recognized by the FDA with Orphan Drug and Fast Track designations, targets the Dickkopf-1 protein, crucial in tumor biology and immunosuppression.
Leap Therapeutics (Nasdaq:LPTX) announced that the FDA has granted Fast Track designation to its drug DKN-01 for treating gastric and gastroesophageal junction adenocarcinoma in patients whose tumors express high Dickkopf-1 (DKK1) protein after prior chemotherapy. This designation aims to expedite the drug's development and review, enabling faster access for patients with unmet medical needs. DKN-01 is also undergoing trials for various cancers and has received Orphan Drug Designation for gastric and gastroesophageal junction cancers.